y 590 has been researched along with milrinone in 2 studies
| Studies (y 590) | Trials (y 590) | Recent Studies (post-2010) (y 590) | Studies (milrinone) | Trials (milrinone) | Recent Studies (post-2010) (milrinone) |
|---|---|---|---|---|---|
| 5 | 0 | 0 | 1,605 | 235 | 452 |
| Protein | Taxonomy | y 590 (IC50) | milrinone (IC50) |
|---|---|---|---|
| Phosphodiesterase | Bos taurus (cattle) | 1 | |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.3 | |
| High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | Homo sapiens (human) | 0.3 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.52 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 4.7 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 3.15 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 1.8674 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 1.8177 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Bos taurus (cattle) | 5 | |
| Phosphodiesterase | Sus scrofa (pig) | 0.843 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bristol, JA; Humblet, CC; McPhail, AT; Moos, WH; Rithner, C; Sircar, I; Weishaar, RE | 1 |
| Beedle, EE; Hayes, JS; Kauffman, RF; Krushinski, JH; Pollock, GD; Robertson, DW; Wilson, H; Wyss, V | 1 |
2 other study(ies) available for y 590 and milrinone
| Article | Year |
|---|---|
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Myocardial Contraction; Spectrophotometry, Infrared; X-Ray Diffraction | 1987 |
Dihydropyridazinone cardiotonics: the discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H -indol-2- one.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Cats; Dogs; Female; In Vitro Techniques; Indoles; Male; Myocardial Contraction; Oxindoles; Platelet Aggregation; Pyridazines; Structure-Activity Relationship | 1986 |